866 Days Left

Biomedical Catalyst 2021 Round 2: Feasibility & Primer Awards

Fund Name

Biomedical Catalyst 2021 Round 2: Feasibility & Primer Awards

Project Length

3 - 24 months

Project Value

Up to £1m



The aim of the Biomedical Catalyst 2021 Round 2 competition is to explore and evaluate the commercial potential of an innovative scientific idea or carry out a technical evaluation through to proof of concept in a model system. Projects should focus on the development of a product or process that is an innovative solution to a healthcare challenge. Your project can focus on:

  • Disease prevention and proactive management of health and chronic conditions
  • Earlier and better detection and diagnosis of disease, leading to better patient outcomes
  • Tailored treatments that either change the underlying disease or offer potential cures

Check Your Eligibility

Fund Details

This competition combines the feasibility and primer strands of the Biomedical Catalyst:

  • The feasibility award is designed for projects that have developed an innovative concept or carried out experimental proof of concept but have not validated the technology. The aim of the feasibility award is to explore and evaluate the commercial potential of innovative ideas.
  • The primer award is for conducting a technical evaluation of an idea through to proof of concept in a model system.

Your project can:

  • Review research evidence and identify possible applications
  • Assess business opportunities
  • Assess or protect intellectual property
  • Validate initial concepts and existing pre-clinical work through experimental studies
  • Initially demonstrate using in-vitro and in-vivo models, but not human clinical trials
  • Develop early-stage prototyping
  • Acquire preliminary regulatory advice

Innovate UK particularly welcomes applications that support innovation in the following areas:

  • Child health technologies
  • Innovations that support clinical trials in the UK
  • Biomedical innovations that combat the threat of antimicrobial resistance

Your project can align with one or more of the following:

  • Medical technologies and devices
  • Stratified healthcare
  • Advanced therapies such as gene and cell therapies
  • Digital health
  • Drug discovery
  • Diagnostics


Your project must:

  • Have total eligible costs between £50,000 and £1 million
  • Start on 1 April 2022
  • End by 31 March 2024
  • Last between 3 months and 24 months
  • Carry out all of its project work in the UK
  • Intend to exploit the results from or in the UK

To collaborate with the lead, your organisation must be a UK registered business of any size, academic institution, charity, not-for-profit, public sector organisation, research and technology organisation (RTO). Innovate UK will not fund projects that are:

  • In scope for the Biomedical Catalyst early-stage or late-stage awards
  • Not related to human life sciences
  • Already on the market
  • Laboratory accreditation
  • Conducted to anything less than the highest standards of animal welfare
  • Dependent on export performance
  • Dependent on domestic inputs usage

Talk to us today if you would like to apply for this opportunity.

Contact us